|Bid||32.10 x 1000|
|Ask||32.22 x 200|
|Day's Range||32.10 - 33.09|
|52 Week Range||27.60 - 56.44|
|PE Ratio (TTM)||412.31|
|Dividend & Yield||1.36 (4.13%)|
|1y Target Est||N/A|
Yitzhak Peterburg, interim president and CEO of Teva Pharmaceutical, talks about the disruption facing the traditional health care industry.
Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.
Shares of Valeant Pharmaceuticals International (VRX) spiked yesterday on speculation regarding a possible debt-to-equity swap by the troubled drug maker. Wells Fargo analyst David Maris weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts. As Maris writes: Based on our experience and feedback from our high yield debt analyst, we think that most debt holders do not have the ability or interest to take cross structure risk.